SecBot SecBot
SECBOTREPLAY Home › Report › RARE

RARE · Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc. · 8-K filed Apr 2, 2026 at 08:45 ET

At the news

BULLISHIMPACT 8/10

8-K filed Apr 2, 2026 at 08:45 ET

Ultragenyx Pharmaceutical Inc. announced that the FDA has accepted for review its resubmitted Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec), an AAV9 gene therapy for Sanfilippo syndrome Type A (MPS IIIA), with a PDUFA action date of September 19, 2026. This marks a key regulatory milestone for a potential first-in-class therapy for a rare and severe pediatric neurodegenerative disease.

  • FDA accepted resubmitted BLA for UX111 (rebisufligene etisparvovec) for accelerated approval
  • Indication: Sanfilippo syndrome Type A (MPS IIIA), a rare pediatric neurodegenerative disorder
  • PDUFA action date set for September 19, 2026
  • Therapy is an AAV9 gene therapy, representing a potential one-time treatment

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access